pharmaquotient.com

60 POSTS0 COMMENTS

http://pharmaquotient.com

Regulatory update

Daiichi’s mRNA COVID-19 Booster Vaccine Approved in Japan

pharmaquotient.com - 2 August 2023 0

Regulatory update

China’s NMPA Accepts Astellas’ Biologics License Application for Zolbetuximab

pharmaquotient.com - 1 August 2023 0

generic

Viatris Announces Launch of Breyna™ Generic Version of Symbicort®

pharmaquotient.com - 31 July 2023 0

Weekly News Updates

Weekly Pharma News for the week ending 31-July-23

pharmaquotient.com - 31 July 2023 0

Merger & Acquisition

Biogen to buy Reata Pharmaceuticals for up to $7.3 B

pharmaquotient.com - 28 July 2023 0

Appointments

AstraZeneca appoints Sharon Barr as EVP of Biopharmaceutical R&D

pharmaquotient.com - 28 July 2023 0

Appointments

Teva Appoints Dr. Angus Grant to Executive Vice President, Business Development

pharmaquotient.com - 27 July 2023 0

Partnership agreement

Teva & Alvotech Provide Update on Strategic Biosimilars Partnership

pharmaquotient.com - 24 July 2023 0

Regulatory update

Sandoz Receives Positive CHMP Opinion for Tysabri’s Biosimilar Natalizumab

pharmaquotient.com - 24 July 2023 0

Pharma Deals

Flagship Pioneering Partners with Pfizer to Bolster Development of Innovative Medicine for $50M upfront

pharmaquotient.com - 18 July 2023 1

1...4 56Page 6 of 6

TOP AUTHORS

constance80t

0 POSTS0 COMMENTS

Neha Tripathi

1 POSTS0 COMMENTS

http://pharmaQuotient.com

pharma analyst

0 POSTS0 COMMENTS

pharmaquotient.com

60 POSTS0 COMMENTS

http://pharmaquotient.com

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

20 September 2024

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

17 September 2024

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

9 September 2024

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

7 September 2024

pharmaquotient.com

TOP AUTHORS

Most Read

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

EDITOR PICKS

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

POPULAR POSTS

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

POPULAR CATEGORY

ABOUT US

FOLLOW US